Dova Pharmaceuticals Profile

Performance

1313

Odds of Distress

Analyze Filter    Earnings Report: March 3, 2020
Equity ratings for Dova Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 11, 2019 and ending today December 10, 2019. Click here to learn more.

Dova Pharmaceuticals Profile

Next earnings report is expected on March 3, 2020. Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina. Dova Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 115 people. more
NameDova Pharmaceuticals
President CEO, DirectorAlex SapirView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address240 Leigh Farm Road, Suite 245, Durham, NC 27707, United States
ExchangeBATS Exchange
CIK Number0001685071
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.dova.com
Phone919 748 5975
CurrencyUSD - US Dollar
Dova Pharmaceuticals (DOVA) is traded on BATS Exchange in USA and employs 115 people. The company currently falls under 'Small-Cap' category with current market capitalization of 807.61 M. Dova Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 28.8 M outstanding shares of which 1.19 M shares are currently shorted by private and institutional investors with about 1.08 trading days to cover. The company currently holds about 76.78 M in cash with (57.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67.
Check Dova Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Dova Pharmaceuticals Target Price Odds Analysis

Odds Below 28.04HorizonTargetOdds Above 28.04
70.29%30 days 28.04 29.63%
Based on normal probability distribution, the odds of Dova Pharmaceuticals to move above current price in 30 days from now is about 29.63 (This Dova Pharmaceuticals probability density function shows the probability of Dova Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Dova Pharmaceuticals Top Holders

Dova Pharmaceuticals Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Dova Pharmaceuticals Key Fundamentals

Dova Pharmaceuticals Against Markets

Did you try this?

Run Chance of Distress Now

   

Chance of Distress

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module

Dova Pharmaceuticals Upcoming and Recent Events

Dova Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportNovember 14, 2019
Next Earnings ReportMarch 3, 2020
Next Fiscal Quarter EndSeptember 30, 2019
Next Fiscal Year EndMarch 3, 2020
Last Quarter Report DateJune 30, 2019
Last Earning Anouncement DateSeptember 30, 2018

Dova Pharmaceuticals Corporate Filings

Dova Pharmaceuticals SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
Submission of Matters to a Vote of Security Holders
Entry into a Material Definitive Agreement

Dova Pharmaceuticals Corporate Directors

Steven Goldman Independent Director
Alfred Novak Independent Director
Sean Stalfort Director
Additionally see Investing Opportunities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Search macroaxis.com